Using mouse models, several approaches, including the use of specific antibodies, antagonists, or siRNA, have been used to block the CCL22/CCL17 – CCR4 axis, resulting in reduction in Treg frequencies and a concomitant increase in anti-tumor activity (40, –42). Here, CCR4 is linked to neoplasm.